Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2026-04-12 @ 8:34 AM
Study NCT ID:
NCT00560794
Status:
COMPLETED
Last Update Posted:
2015-01-26
First Post:
2007-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Sponsor:
Amgen Research (Munich) GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-01
Start Date Type:
None
Primary Completion Date:
2009-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-11
Completion Date Type:
ACTUAL
First Submit Date:
2007-11-19
First Submit QC Date:
None
Study First Post Date:
2007-11-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-12-23
Results First Submit QC Date:
None
Results First Post Date:
2015-01-07
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-01-12
Last Update Post Date:
2015-01-26
Last Update Post Date Type:
ESTIMATED